Precision BioSciences (NASDAQ:DTIL) Issues Earnings Results

Precision BioSciences (NASDAQ:DTIL) posted its earnings results on Thursday. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.46), FiscalAI reports. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 67.70%.

Precision BioSciences Price Performance

Precision BioSciences stock traded up $0.07 during trading hours on Friday, hitting $7.49. 240,103 shares of the company traded hands, compared to its average volume of 341,234. The firm has a market cap of $193.24 million, a P/E ratio of -2.67 and a beta of 1.27. The company has a quick ratio of 14.02, a current ratio of 14.02 and a debt-to-equity ratio of 0.29. The firm’s 50-day simple moving average is $7.36 and its two-hundred day simple moving average is $6.33. Precision BioSciences has a 1-year low of $3.53 and a 1-year high of $9.62.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on DTIL shares. Oppenheimer assumed coverage on shares of Precision BioSciences in a report on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 price objective on the stock. HC Wainwright restated a “buy” rating on shares of Precision BioSciences in a research report on Monday, August 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Precision BioSciences in a research note on Wednesday. Wall Street Zen cut Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday. Finally, JonesTrading reiterated a “buy” rating and set a $30.00 price objective on shares of Precision BioSciences in a research report on Friday, April 17th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP acquired a new position in shares of Precision BioSciences during the fourth quarter valued at approximately $43,000. Occudo Quantitative Strategies LP bought a new stake in Precision BioSciences during the fourth quarter worth approximately $52,000. Virtu Financial LLC acquired a new stake in Precision BioSciences in the third quarter worth approximately $84,000. Velan Capital Investment Management LP acquired a new stake in Precision BioSciences in the third quarter worth approximately $110,000. Finally, Citadel Advisors LLC bought a new position in Precision BioSciences during the 3rd quarter valued at $122,000. 37.99% of the stock is currently owned by institutional investors.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.